NCT02595762View on ClinicalTrials.gov

A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

October 30, 2016

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Metastatic Breast CancerLocally Advanced Breast Cancer
Trial Locations (12)

2006

Bank of Cyprus Oncology Center, Nicosia

11525

251 Air Force General Hospital-Oncology Clinic, Athens

115 22

Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens

Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens

115 28

ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens

145 64

Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens

151 23

IASO, Athens

155 62

IASO General Hospital of Athens, Athens

124 62

Attikon University Hospital; 4th Department of Internal Medicine, Haidari

185 47

Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus

546 39

Theagenio Anticancer Hospital; 3Rd Oncology Clinic, Thessaloniki

564 29

Papageorgiou General Hospital; Medical Oncology, Thessaloniki

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02595762 - A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter